Intrinsiqs

Is Coherus Oncology, Inc. overvalued?

Coherus Oncology, Inc. (CHRS) — key valuation metrics and fundamentals.

No verdict
Price
$1.14
Fair value
—
Current P/E
—
Normal P/E
9.4
Market cap
$176.1M
Dividend yield
0.0%
Return on equity
-181.7%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CHRS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.